Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 13

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 13
---
 DATA</div>

This prospectus contains estimates,
projections and other information concerning our industry, our business and the market for our product candidates. Information that is
based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual
events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly
stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports,
research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications,
government data and similar sources. While we believe our internal company research as to such matters is reliable and the market definitions
are appropriate, neither such research nor these definitions have been verified by any independent source.

In addition, assumptions and
estimates of our and our industry’s future performance are necessarily subject to a high degree of uncertainty and risk due to a
variety of factors, including those described in the section titled “Risk Factors.” These and other factors could cause
our future performance to differ materially from our assumptions and estimates. See “Cautionary Note Regarding Forward-Looking Statements.”

<div align='center'>WEBSITE DISCLAIMER</div>

We maintain a public website
at https://www.biodexapharma.com and use our website as a route channel of distribution of company information, including press releases
and presentations. Our website includes an “Investors” section through which we make available, free of charge, our Annual
Report on Form 20-F, Reports on Form 6-K, as well as any amendments to those reports filed or furnished pursuant to the Exchange Act as
soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Accordingly, investors should
monitor our website in addition to following press releases, filings with the SEC and public conference calls and webcasts.

None of the information
provided on our website, in our press releases or public conference calls and webcasts or through social media is incorporated into, or
deemed to be part of, this prospectus or any other report or document we file with the SEC, and any references to such website is intended
to be inactive textual references only.

| 4 |

PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before deciding to invest in our securities, you